NCT07107633View on ClinicalTrials.gov

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Solid TumorPeritoneal Metastasis

Interventions

DRUG

Technetium [99mTc]-H7ND injection

Technetium \[99mTc\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor

Trial Locations (1)

Unknown

RECRUITING

Zhongshan Hospital Affiliated to Fudan University, Shanghai

All Listed Sponsors

lead

Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.

OTHER

NCT07107633 - A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor. | Biotech Hunter | Biotech Hunter